SCHEMBL4835594

SCHEMBL4835594

CC(C)(C)OC(=O)CC(CCC(=O)NOC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
KCNH2 Q12809 1/20 0.47
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
LTA4H P09960 1/20 0.36
SLC1A1 P43005 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SLC1A2 P43004 1/20 0.36
ACE P12821 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
SLC15A1 P46059 2/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4837207 0.89 CYP3A4 (0.44) CYP3A4CYP2C9KCNH2CA2CA9
SCHEMBL4837398 0.82 KMT2A (0.44) CYP3A4CYP2C9KCNH2CA2CA9
SCHEMBL4831400 0.81 CYP3A4 (0.38) CYP3A4CYP2C9KCNH2CA2CA9
SCHEMBL4831392 0.81 CA2 (0.43) CYP3A4CYP2C9KCNH2CA2CA9
SCHEMBL4839501 0.77 L3MBTL1 (0.49) CYP3A4CYP2C9KCNH2CA2CA9
SCHEMBL4835726 0.75 KIF11 (0.42)
SCHEMBL4840448 0.75 L3MBTL1 (0.43) CYP3A4CYP2C9KCNH2CA2CA9
SCHEMBL4838181 0.75 CYP3A4 (0.36) CYP3A4CYP2C9KCNH2CA2CA9
SCHEMBL4838164 0.75 NPC1 (0.48) CYP2C9CA2CA9KDM4EL3MBTL1
SCHEMBL4831283 0.75 CA2 (0.49) CYP3A4CYP2C9KCNH2CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD CYP3A4 1480/4885CYP2C9 1090/4885KCNH2 4714/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD CYP3A4 1294/4885CYP2C9 940/4885KCNH2 4702/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH CYP3A4 1300/4885CYP2C9 941/4885KCNH2 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.